Synonym
Krm 1657; Krm-1657; Krm1657
IUPAC/Chemical Name
Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-1-oxo-5'-(4-propyl-1-piperazinyl)-
InChi Key
KDFFQLYROXGQFM-VDPAUJFTSA-N
InChi Code
InChI=1S/C50H62N4O13/c1-11-16-53-17-19-54(20-18-53)31-22-32(56)38-34(23-31)66-47-39(51-38)35-36-43(59)29(7)46-37(35)48(61)50(9,67-46)64-21-15-33(63-10)26(4)45(65-30(8)55)28(6)42(58)27(5)41(57)24(2)13-12-14-25(3)49(62)52-40(47)44(36)60/h12-15,21-24,26-28,33,41-42,45,56-59H,11,16-20H2,1-10H3,(H,52,62)/b13-12+,21-15+,25-14-/t24-,26+,27+,28+,33-,41-,42+,45+,50-/m0/s1
SMILES Code
CCCN1CCN(c2cc3c(N=C4C(O3)=C5NC(/C(C)=C\C=C\[C@@H](c(O)c(C)c([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@]6(Oc7c(C6=O)c4c(C5=O)c(O)c7C)C)OC)C)OC(C)=O)C)O)C)=O)c(O)c2)CC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
924.04
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fujii K, Tsuji A, Miyazaki S, Yamaguchi K, Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother. 1994 May;38(5):1118-22. doi: 10.1128/AAC.38.5.1118. PMID: 8067748; PMCID: PMC188160.
2: Akada JK, Shirai M, Fujii K, Okita K, Nakazawa T. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother. 1999 May;43(5):1072-6. doi: 10.1128/AAC.43.5.1072. PMID: 10223916; PMCID: PMC89113.
3: Saito H, Tomioka H, Sato K, Emori M, Yamane T, Yamashita K, Hosoe K, Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 Mar;35(3):542-7. doi: 10.1128/AAC.35.3.542. PMID: 2039206; PMCID: PMC245047.
4: Dhople AM, Ibanez MA. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J Antimicrob Chemother. 1995 Apr;35(4):463-71. doi: 10.1093/jac/35.4.463. PMID: 7628981.
5: Kuze F. [Antimycobacterial activities of rifamycin derivatives]. Kekkaku. 1991 Oct;66(10):679-85. Japanese. PMID: 1960916.
6: Dhople AM. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae. Indian J Lepr. 1997 Oct-Dec;69(4):377-84. PMID: 9474513.
7: Heep M, Lehn N, Brandstätter B, Rieger U, Senzenberger S, Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2002 Feb;21(2):143-5. doi: 10.1007/s10096-001-0672-2. PMID: 11939398.
